Bausch & Lomb (TSX:BLCO) Current Accrued Expense : C$529 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Current Accrued Expense?

Bausch & Lomb's Current Accrued Expense for the quarter that ended in Dec. 2023 was C$529 Mil.

Bausch & Lomb's quarterly Current Accrued Expense declined from Jun. 2023 (C$902 Mil) to Sep. 2023 (C$383 Mil) but then increased from Sep. 2023 (C$383 Mil) to Dec. 2023 (C$529 Mil).

Bausch & Lomb's annual Current Accrued Expense increased from Dec. 2021 (C$287 Mil) to Dec. 2022 (C$493 Mil) and increased from Dec. 2022 (C$493 Mil) to Dec. 2023 (C$529 Mil).

Bausch & Lomb Current Accrued Expense Historical Data

The historical data trend for Bausch & Lomb's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Current Accrued Expense Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

277.87

254.90

286.72

493.14

528.59

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial											493.14	368.07	902.12	382.93	528.59

Bausch & Lomb Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Bausch & Lomb Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (TSX:BLCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

BLCO:USA S2L:Germany

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.